An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma

Trial Profile

An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs KA 2237 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Karus Therapeutics
  • Most Recent Events

    • 21 Dec 2016 Planned number of patients changed to 53.
    • 05 Oct 2016 According to Karus Therapeutics media release, the first patients have been dosed in first cohort of this study, an expansion cohort will follow and is scheduled to start in 2017. Up to 40 patients will be treated over the entire study.
    • 10 Aug 2016 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top